Primary cells are extracted from a living tissue and are grown in vitro conditions. Primary cells are extracted from various living beings and are used for various purposes, which helps in highlighting the differences amongst the humans and the preclinical test species. In the initial stages, mice and rats cell and tissues were used to experiment in vivo conditions to refine the doses and also to reduce the animal count used for the preclinical toxicology. Human cells are also been used for helping in determining the accuracy of extrapolating human data from an animal model.
Primary cells are also called mature cells. They are considered to be the most advantageous cells for the immunological compatibility but they are differentiated in nature. As they are already in the post-mitotic stage they have lost the ability to divide any further. Additionally, the proliferation potential of these cells is low as compared to other cells in the body.
COVID-19 scenario analysis:
Pharmaceutical and biotech companies together with governments around the globe are working to address the COVID-19 outbreak, from supporting the development of vaccines to planning for medicines supply chain challenges. Currently, around 115 vaccine candidates and 155 molecules are in the R&D pipeline. Moreover, commonly used drugs such as Hydroxychloroquine have witnessed a dramatic surge in demand for the management of COVID-19. Such high demand for these drugs has presented huge opportunities for manufacturers of COVID-19 management drugs, as many developed countries are short of these drugs. Owing to the demand for vaccine and treatment drugs for COVID-19, the pharmaceutical and biotechnology industry is expected to witness a significant growth in the future.
Owing to such factors, COVID 19 is expected to have a significant impact on the Primary Cells market.
Top impacting factors: Market Scenario Analysis, Trends, Drivers and Impact Analysis:
High frequency of cancer cases, rising cancer research activities, research funding have also been increasing new cancer therapy options are the main factors driving the primary cells market.
In the case of cancer research, primary cells are considered as the most ideal models for biomarker discovery and cancer drug screening. Along with this, primary human cells have various other advantages when the in vitro cell lines are considered. For instance, primary cells furnish a compatible tissue-specific response in a microenvironment. Moreover, primary human cells are also capable of decreasing the expense of the animal models in vivo studies and are economically compatible. Pre-screened cells are used in the study of in vivo signaling. Owing to the above factors, pharmaceutical and biotechnology companies along with CROs are increasing the consumption of primary cells in their processes of drug discovery.
During cancer research, primary cells are exposed to chemicals, heavy radiation doses, viruses, which help in the transformation of the primary cells to cancer cells by genetic mutations, and oncogenes introduction.
Primary cells have different advantages in vitro cell lines which help in providing various dependable responses that are specific to the tissues in a biologically applicable microenvironment.
Additionally, primary cells are very profitable and are used for investment reductions on animal models which are needed in vivo.
On the other hand, there are many concerns in regards to the primary cell culture contamination, the expensive processes and the restrictions applied to the utilization of raw material are the major challenges faced in the primary cell market.
New product launches to flourish the market:
On June 1st, 2018, Lonza launched its new primary cells portfolio which included hepatic stellate cells, liver-derived endothelial cells, and Kupffer cells.
On April 25th, 2018, STEMCELL technologies obtained an amount of US $ 45 million from Canada and British Columbia which helped the company in building an advanced manufacturing facility in British Columbia.
Surge in usage in research institutions and companies applications:
Research institutes and companies are the major consumers of primary cells. Amongst them, life science research companies constitute the highest shareholders. The growth rate is constantly increasing owing to the high acceptance of primary cells by the companies for the experiments on various cell functions and research on the cancer sector. This has also increased the number of research and development facilities all over the world.
Key benefits of the report:
- This study presents the analytical depiction of the global Primary Cells industry along with the current trends and future estimations to determine the imminent investment pockets.
- The report presents information related to key drivers, restraints, and opportunities along with detailed analysis of the global Primary Cells market share.
- The current market is quantitatively analyzed to highlight the global market growth scenario.
- Porter’s five forces analysis illustrates the potency of buyers & suppliers in the market.
- The report provides a detailed global Primary Cells market analysis based on competitive intensity and how the competition will take shape in coming years.
Questions answered in the Primary Cells Market research report:
- What are the leading market players active in the Primary Cells market?
- What the current trends will influence the market in the next few years?
- What are the driving factors, restraints, and opportunities in the market?
- What are the projections for the future that would help in taking further strategic steps?
Primary Cells Market Report Highlights
| Aspects | Details |
 By Origin |
|
 By Type |
|
 By End User |
|
 By Region |
|
 Key Market Players | PromoCell, STEMCELL Technologies, Thermo Fisher Scientific, Cell Biologics, Lonza, Merck KGaA, AllCells, ZenBio, American Type Culture Collection, Axol Biosciences. |
Loading Table Of Content...
